Growth Hormone Insensitivity Syndrome

1. Disease Information

Overview. Growth Hormone Insensitivity Syndrome (Laron syndrome) is an autosomal recessive disorder of severe postnatal growth failure caused by the inability to generate insulin-like growth factor-1 (IGF-1) in response to growth hormone (GH). The defining biochemical hallmark is high or normal circulating GH with low serum IGF-1 that fails to rise on GH stimulation — i.e., the pituitary is intact but peripheral tissues are "deaf" to GH. It was first described by the Israeli pediatric endocrinologist Zvi Laron in 1966 in a series of consanguineous Yemenite Jewish families.

Key identifiers: - OMIM: #262500 (Laron syndrome / GH insensitivity, classic GHR-deficiency form); related loci/forms: GHR gene 600946; STAT5B GHI with immune dysregulation #245590 (GHISID1); IGFALS deficiency (ACLSD) #615961; IGF1 deficiency #608747; IGF1R resistance #270450. - MONDO: MONDO:0008638 (Laron syndrome). - Orphanet: ORPHA:633 (Growth hormone insensitivity syndrome / Laron syndrome). - ICD-10: E34.3 (Short stature due to endocrine disorder); ICD-11: 5A60.1 (Growth hormone insensitivity). - MeSH: D046150 "Laron Syndrome." - UMLS/SNOMED CT:* Laron-type dwarfism (e.g., SNOMED 237689005).

Synonyms / alternative names: Laron-type dwarfism; primary growth hormone insensitivity (GHI); growth hormone receptor deficiency (GHRD); Laron-type pituitary dwarfism; severe primary IGF-1 deficiency (SPIGFD — the regulatory/therapeutic term used in the mecasermin label); somatomedin deficiency.

Data derivation. The knowledge is aggregated from disease-level resources (OMIM, Orphanet, GeneReviews) and from a small number of deeply phenotyped cohorts of individual patients — principally the Israeli cohort (assembled by Zvi Laron from 1958; ~64 patients by 2009) and the southern Ecuadorian cohort (~100 individuals, studied by Jaime Guevara-Aguirre). It is not primarily an EHR-derived entity given its rarity.

Sources: OMIM #262500; OMIM *600946 GHR; MedlinePlus: Laron syndrome; NORD: Growth Hormone Insensitivity.

2. Etiology

Primary cause (genetic). Classic Laron syndrome results from biallelic (homozygous or compound heterozygous) loss-of-function mutations in GHR (growth hormone receptor gene, 5p13–p12). Over 70–100 distinct GHR mutations have been catalogued — deletions, nonsense, missense, and splice-site variants — predominantly affecting the extracellular hormone-binding domain, abolishing GH binding or receptor dimerization. Post-receptor and downstream defects (STAT5B, etc.) cause clinically overlapping GHI.

"Laron syndrome is caused by homozygous or compound heterozygous mutation in the growth hormone receptor gene (GHR; 600946)… Over 70 mutations of the GHR gene have been identified including deletions, missense and nonsense point mutations and splice site mutations." — OMIM #262500.

Genetic risk factors. - Causal variants: biallelic GHR LoF (most common). The canonical Ecuadorian founder allele is E180splice (exon 6 splice mutation, c.594A>G); the Israeli/Mediterranean cohorts carry other recurrent alleles. - Other causal genes (broader GHI spectrum): STAT5B (recessive and dominant-negative forms — GHI with immune dysregulation); IGFALS (acid-labile subunit deficiency — milder); IGF1 (IGF-1 deficiency with intrauterine growth restriction, microcephaly, deafness, intellectual disability); IGF1R (IGF-1 resistance); PAPPA2 (impaired IGF-1 bioavailability). A continuum of genetic, biochemical, and phenotypic severity exists across these genes (PMID:21525302). - Modifier loci: variation in IGFBP3, ALS, and the IGF1R axis modulate residual growth.

Environmental risk factors. No environmental cause — the disorder is monogenic. The dominant non-genetic risk factor is consanguinity / population isolation, which raises homozygosity for the recessive allele. Nutrition and intercurrent illness modify the severity of hypoglycemia and growth, not disease occurrence.

Protective factors. Not applicable to disease causation. Notably, the disease state itself is associated with downstream protection against cancer and type 2 diabetes (see §6/§11) — a "protective phenotype," not a protective factor against the disorder.

Gene–environment interactions. Caloric intake and recurrent fasting interact with the impaired counter-regulatory capacity (low IGF-1, enhanced insulin sensitivity) to provoke fasting/ketotic hypoglycemia, especially in infancy.

Sources: OMIM #262500; Genetic causes of GHI beyond GHR (PMC7979432); Genetic defects in the GH–IGF-I axis (PMC3356141); Continuum of GHI abnormalities, PMID:21525302.

3. Phenotypes

Phenotypes cluster into (a) severe proportionate short stature, (b) characteristic craniofacial/somatic features, (c) metabolic abnormalities, and (d) the biochemical signature.

Onset/severity/progression generalities: Birth size is near-normal (IGF-1 prenatally is only partly GH-dependent), with dramatic postnatal growth failure. Short stature is non-progressive but permanent; metabolic features (obesity, insulin sensitivity) evolve over the lifespan.

Quality-of-life impact. Marked short stature affects psychosocial functioning, education/employment, and (structurally) injury risk from falls; obesity and skeletal fragility add morbidity. Cognition is generally normal in classic GHR-deficiency Laron syndrome (in contrast to IGF1-gene defects, which cause intellectual disability and deafness).

Sources: OMIM #262500; Laron syndrome review, In Vivo 2016; Brazilian Laron series, PMC7197995.

4. Genetic / Molecular Information

Causal gene — GHR (HGNC:4263; OMIM *600946; chromosome 5p13–p12). Encodes a 620-aa single-pass transmembrane cytokine-receptor-superfamily protein with an extracellular GH-binding domain (the proteolytically shed portion forms serum GH-binding protein, GHBP), a transmembrane domain, and an intracellular domain coupling to JAK2/STAT5.

Pathogenic variants: - Type/class: the full mutational spectrum — large/partial gene deletions, nonsense, missense (esp. extracellular domain, e.g., disrupting disulfide bonds or dimerization), splice-site (the Ecuadorian E180 splice founder allele), and intronic/pseudoexon variants. Dominant-negative GHR variants in the transmembrane/intracellular region cause milder dominant GHI. - Classification (ACMG/AMP): recurrent founder alleles are classified Pathogenic in ClinVar; many private missense variants are Likely Pathogenic/VUS pending functional data. - Allele frequency: individually ultra-rare in gnomAD; enriched only in founder populations (southern Ecuador, Mediterranean/Middle Eastern consanguineous groups). - Origin: germline, biallelic (recessive). No somatic role. - Functional consequence: loss of function — failure of GH binding, receptor dimerization, or JAK2/STAT5 signal transduction → no IGF-1 transcription. GHBP is low/absent when the defect is in the extracellular domain (a useful biochemical discriminator) but normal/high in transmembrane/intracellular and post-receptor (STAT5B) defects.

Downstream-axis genes (broader GHI): STAT5B (HGNC:11367) — recessive LoF and dominant-negative; IGFALS (HGNC:5466); IGF1 (HGNC:5464); IGF1R (HGNC:5465); PAPPA2 (HGNC:8602). Mechanistic split: IGF-1 deficiency (GHR, STAT5B, IGF1), IGF-1 bioavailability (IGFALS, PAPPA2), IGF-1 resistance (IGF1R).

"Mutations in a number of components along this axis result in GHI and IGF deficiency (STAT5B, IGF1), IGF bioavailability (IGFALS, PAPPA2) or IGF resistance (IGF1R)." — Genetic causes of GHI beyond GHR (PMC7979432).

Modifier genes. Polymorphisms/variants in IGFBP3, IGFALS, and the IGF1R pathway modulate residual linear growth and treatment response.

Epigenetics. No established primary epigenetic mechanism in classic Laron syndrome. Of note, genome-wide profiling of Laron patients identified novel cancer-protection transcriptional/methylation pathways (e.g., differential expression of genes regulating apoptosis, DNA repair, and metabolism) — relevant to the protective phenotype rather than disease causation.

Chromosomal abnormalities. Large multi-exon/whole-GHR deletions occur; otherwise no recurrent aneuploidy or translocation.

Sources: OMIM *600946; GHI beyond GHR (PMC7979432); Dominant-negative STAT5B (PMC5974024); Genome-wide profiling of Laron patients (PMC6627189).

5. Environmental Information

• Environmental factors: none causal. The disorder is fully penetrant monogenic.
• Lifestyle factors: diet and fasting interact with the metabolic phenotype (hypoglycemia risk in infancy; obesity in later life), but do not cause or prevent the disorder.
• Infectious agents: not applicable to classic GHR-deficiency. (In the STAT5B subtype, recurrent infections are a consequence of immune dysregulation, not a trigger.)

Source: MedlinePlus: Laron syndrome.

6. Mechanism / Pathophysiology

Core causal chain (upstream → downstream):

1. Biallelic GHR loss of function (upstream trigger) → GH cannot bind/signal at target cells (chiefly hepatocytes).
2. Failure of JAK2–STAT5B signal transduction. Normally, GH binding induces GHR dimerization → JAK2 activation → STAT5B tyrosine phosphorylation, homodimerization, nuclear translocation, and transcription of IGF1, IGFBP3, and IGFALS.

   "Recruited STAT5B is tyrosine phosphorylated by JAK2, homodimerizes, and translocate[s] to the nucleus, where it binds DNA, regulating production of circulating IGF-I, IGFBP-3 and ALS." — PMC7979432.

3. Hepatic IGF-1 (and IGFBP-3, ALS) production collapses → low circulating IGF-1; the ternary complex (IGF-1/IGFBP-3/ALS) that stabilizes serum IGF-1 is depleted.
4. Loss of negative feedback — IGF-1 normally restrains pituitary GH secretion; its absence causes GH hypersecretion (the paradoxical "high GH, low IGF-1" signature).
5. Downstream phenotype: loss of IGF-1–driven chondrocyte proliferation at the growth plate → severe postnatal linear growth failure; reduced anabolic signaling → altered body composition; impaired counter-regulation → hypoglycemia.

Molecular pathways: GH/GHR → JAK2–STAT5B (canonical), with secondary involvement of PI3K–AKT–mTOR and RAS–MAPK downstream of IGF-1/IGF1R. The disorder is fundamentally a JAK-STAT signaling defect (KEGG/Reactome: GH receptor signaling; JAK-STAT pathway; IGF-1 receptor signaling).

Cellular processes: reduced chondrocyte and osteoblast proliferation (growth plate); altered adipocyte and myocyte anabolism (obesity, sarcopenia); in the protective phenotype, reduced pro-aging signaling, increased apoptosis of damaged cells, and reduced oxidative DNA damage.

"Serum from subjects with GHR deficiency reduced DNA breaks but increased apoptosis in human mammary epithelial cells treated with hydrogen peroxide… [GHRD subjects had] only one nonlethal malignancy and no cases of diabetes, in contrast to a prevalence of 17% for cancer and 5% for diabetes in control[s]." — Guevara-Aguirre et al., Sci Transl Med 2011 (PMID:21325617).

Protein dysfunction: loss of function of the GH receptor (or, in subtypes, of STAT5B as a transcription factor). Extracellular-domain mutants fail to bind GH and reduce serum GHBP; transmembrane/intracellular mutants may bind GH but fail to signal.

Metabolic changes: markedly enhanced insulin sensitivity (low IGF-1 → reduced lipolytic/diabetogenic GH-axis output relative to IGF-1 feedback) despite obesity; tendency to fasting hypoglycemia in infancy; reduced IGF-1–mediated lipid handling.

Immune involvement: none in classic GHR deficiency; central to the STAT5B subtype (STAT5B is also required for regulatory T-cell and NK function → eczema, lymphocytic interstitial pneumonitis, autoimmunity, recurrent infection).

Tissue damage mechanisms: primarily developmental/anabolic deficit rather than active tissue destruction; skeletal fragility (osteopenia) is a downstream consequence.

Molecular profiling: transcriptomic/genome-wide profiling of Laron patient cells shows differential regulation of cancer-, apoptosis-, and metabolism-related genes underpinning the cancer-protective phenotype (PMC6627189).

Suggested ontology terms: - GO biological process: GO:0060396 growth hormone receptor signaling pathway; GO:0007259 receptor signaling pathway via JAK-STAT; GO:0048009 IGF receptor signaling pathway; GO:0040007 growth; GO:0035556 intracellular signal transduction. - CL cell types: CL:0000182 hepatocyte; CL:0000138 chondrocyte; CL:0000062 osteoblast; CL:0000136 adipocyte; CL:0000084 T cell (STAT5B subtype). - CHEBI: CHEBI:37845 (somatotropin/GH); IGF-1 (peptide hormone); CHEBI for mecasermin/IGF-1 therapeutic.

Sources: Guevara-Aguirre 2011, PMID:21325617; GHI beyond GHR (PMC7979432); Genome-wide profiling (PMC6627189).

7. Anatomical Structures Affected

• Organ/system level:
• Endocrine system (primary) — GH–IGF-1 (somatotropic) axis; pituitary (GH hypersecretion), liver (principal failed IGF-1 source).
• Musculoskeletal system — growth plate / long bones (UBERON:0006255 growth plate; UBERON:0002481 bone tissue), reduced bone mass, small hands/feet, limited joint extension, hip degeneration.
• Reproductive — small genitalia/micropenis, delayed puberty.
• Integumentary — thin skin, sparse hair.
• Body composition — increased adipose tissue, reduced skeletal muscle.
• STAT5B subtype: lungs (interstitial disease), immune organs.
• Tissue/cell level: growth-plate chondrocytes (CL:0000138), osteoblasts (CL:0000062), hepatocytes (CL:0000182), adipocytes (CL:0000136).
• Subcellular level: plasma membrane (GHR; GO:0005886); cytoplasm/JAK2 docking; nucleus (STAT5B-mediated transcription; GO:0005634).
• Localization / lateralization: systemic and bilateral/symmetric (a generalized endocrine signaling defect, not focal).

Suggested UBERON terms: UBERON:0006255 (growth plate); UBERON:0002107 (liver); UBERON:0000007 (pituitary gland); UBERON:0002481 (bone tissue); UBERON:0001013 (adipose tissue).

8. Temporal Development

• Onset: congenital (genetic) with postnatal clinical emergence. Birth length is near-normal; growth failure becomes evident within the first 1–2 years. Neonatal hypoglycemia and micropenis can present in the newborn period.
• Onset pattern: chronic/insidious for growth; episodic for hypoglycemia.
• Progression / stages: infancy (hypoglycemia, growth failure, hypotonia) → childhood (established severe short stature, characteristic facies) → adolescence (delayed puberty, eventual spontaneous but delayed sexual maturation) → adulthood (final short stature, central obesity, insulin sensitivity, osteopenia). Short stature is permanent and non-progressive once growth ceases; metabolic features evolve.
• Course: chronic, lifelong, stable (not relapsing-remitting). No spontaneous remission.
• Critical window for intervention: early childhood, before growth-plate fusion — rhIGF-1 therapy started young yields the greatest height benefit; benefit falls sharply after puberty/epiphyseal closure.

Sources: OMIM #262500; Near-adult height IGFD registry, PMID:40626687.

9. Inheritance and Population

Epidemiology. - Prevalence: ultra-rare, estimated ~1–9 per 1,000,000. Roughly 350 patients described worldwide (with substantial under-diagnosis likely). - Geographic clustering: two large founder cohorts — southern Ecuador (~100 individuals, the world's largest cluster) and Israel/Mediterranean (~64–69 individuals); additional cases in Brazil, Chile, Mexico, and the broader Middle East. Genetic evidence links several New World/Mediterranean cohorts to a common ancestral (likely Sephardic converso) origin.

Genetic transmission (classic GHR deficiency): - Inheritance: autosomal recessive (dominant GHI exists with dominant-negative GHR or STAT5B variants but is milder). - Penetrance: essentially complete for biallelic LoF. - Expressivity: variable (final height spans roughly −4 to −10 SDS depending on allele/genetic background). - Anticipation: none (not a repeat-expansion disorder). - Germline mosaicism: not a recognized feature. - Founder effects: prominent — the Ecuadorian E180 splice allele and Mediterranean recurrent alleles. - Consanguinity: a major driver of homozygosity and regional clustering. - Carrier frequency: elevated only within founder/consanguineous populations; negligible in the general population.

Demographics: - Affected populations: enriched in southern Ecuadorian, Sephardic/Mediterranean Jewish, Middle Eastern, and other consanguineous communities. - Sex ratio: roughly equal (1:1) — autosomal; males are more clinically conspicuous (micropenis). - Age distribution: diagnosed in infancy/early childhood; cohorts now include long-surviving adults.

Sources: OMIM #262500; MedlinePlus; In Vivo 2016 clinical/molecular review; Zvi Laron / cohort history (Healio).

10. Diagnostics

Biochemical (the cornerstone): - Low serum IGF-1 (often undetectable) with normal or elevated basal GH (LOINC: IGF-1 [e.g., 2484-4]; GH). - Failure of IGF-1 to rise on IGF-1 generation test (GH stimulation) — the functional confirmatory test distinguishing GHI from GH deficiency. - Low IGFBP-3 and low ALS (acid-labile subunit). - Low/absent GHBP (growth hormone–binding protein) — supports an extracellular-domain GHR defect; normal GHBP points to transmembrane/intracellular or post-receptor (STAT5B) causes. - Ancillary: fasting hypoglycemia, low fasting glucose with relatively high insulin sensitivity; elevated cholesterol in some.

Imaging / functional: - Bone-age radiograph (delayed); skeletal survey shows thin cortices, small facial bones. - DXA — osteopenia/low bone mass. - Pituitary MRI typically normal (distinguishes from organic GH deficiency).

Genetic testing (confirmatory): - Single-gene GHR sequencing (first-line when the phenotype/biochemistry is classic) including deletion/duplication analysis (MLPA) for whole/partial-gene deletions. - Targeted GHI/short-stature gene panel (GHR, STAT5B, IGFALS, IGF1, IGF1R, PAPPA2) when GHBP is normal or features (immune dysregulation, microcephaly/deafness) suggest a downstream cause. - WES/WGS for atypical/unsolved cases. - Chromosomal microarray to exclude deletions overlapping GHR.

Clinical criteria (Laron/consensus, simplified): severe short stature (height ≤ −3 SDS) + low IGF-1 + normal/high GH + subnormal IGF-1 response to GH, with supportive low IGFBP-3/ALS/GHBP.

Differential diagnosis: - GH deficiency (low GH and low IGF-1; responds to GH — opposite GH pattern). - Malnutrition / chronic illness / poorly controlled diabetes / hepatic disease (acquired low IGF-1). - GH gene/biologically inactive GH variants. - IGF-1 / IGF1R / IGFALS / PAPPA2 defects (distinguished by panel + GHBP, IGFBP-3/ALS, IGF-1 levels — IGF1R defects show high IGF-1). - Secondary (acquired) GH insensitivity — antibodies, systemic disease.

Screening: no population newborn screening; cascade carrier testing and prenatal/preimplantation genetic testing are offered in known founder families via genetic counseling.

Sources: GHI beyond GHR (PMC7979432); OMIM #262500; Brazilian series, PMC7197995.

11. Outcome / Prognosis

Survival / mortality. Life expectancy is generally near-normal. In the Ecuadorian cohort, lifespan is comparable to unaffected relatives; accidents and alcohol-related deaths (with structural vulnerability to falls) are leading causes — not cancer or cardiovascular disease.

"The individuals with GHR deficiency exhibited only one nonlethal malignancy and no cases of diabetes, in contrast to a prevalence of 17% for cancer and 5% for diabetes in control subjects." — Guevara-Aguirre 2011 (PMID:21325617).

Morbidity / function. Untreated: severe short stature with attendant functional/psychosocial impact; obesity; osteopenia/fractures; hip degeneration. Cognition is normal in classic GHR deficiency. A striking feature is the protective metabolic phenotype — near-absence of type 2 diabetes and very low cancer incidence, attributed to lifelong low IGF-1/reduced pro-aging signaling; some data also suggest cognitive/memory advantages.

Disease course / complications. Hypoglycemia (infancy), obesity-related metabolic features (despite preserved insulin sensitivity), skeletal fragility; for the STAT5B subtype, immune complications (interstitial lung disease, recurrent infection, autoimmunity) can be life-threatening.

Prognostic factors for growth outcome. Age at rhIGF-1 initiation (earlier = better), baseline height SDS, genotype/residual signaling, treatment adherence, and pubertal status.

Sources: Guevara-Aguirre 2011, PMID:21325617; Scientific American summary; USC memory study.

12. Treatment

Pharmacotherapy — the mainstay: recombinant human IGF-1 (rhIGF-1, mecasermin / Increlex). - Mechanism: bypasses the receptor/signaling block by directly supplying IGF-1, restoring growth-plate signaling. GH itself is ineffective (the defect is GH resistance). - Regulatory status: FDA-approved (2005) and EMA-approved for long-term treatment of growth failure in severe primary IGF-1 deficiency (SPIGFD), including Laron syndrome. A combination product (mecasermin rinfabate, IGF-1 + IGFBP-3) was previously available. - Dosing: twice-daily subcutaneous injection, titrated; administer with meals to avoid hypoglycemia.

"Mecasermin, recombinant human IGF-1, is … FDA-approved for the long-term treatment of growth failure in children with severe primary IGF-I deficiency (Laron syndrome)." — NCBI/CADTH review.

• Efficacy: height velocity rises markedly in the first year (early trials: ~7.8–8.4 cm/yr in the first 6 months, PMID:8334752); real-world IGFD registry data confirm improved near-adult height, though gains are less than in GH-treated GH-deficient children and are blunted by late start (PMID:40626687). A 22-year Saudi cohort confirms long-term height benefit and safety.
• Adverse events: hypoglycemia (most important — dose with food), lipohypertrophy at injection sites, tonsillar/adenoid hypertrophy, intracranial hypertension, slipped capital femoral epiphysis, and theoretical long-term neoplasia/IGF-1–driven concerns (monitored). In trials, ~83% had ≥1 adverse event.

Supportive / adjunctive care. - Treat/prevent hypoglycemia (frequent feeds in infancy). - Manage obesity and metabolic features; monitor bone health. - Endocrine management of puberty as needed. - STAT5B subtype: management of immune dysregulation/interstitial lung disease (immunomodulation, infection prophylaxis).

Surgical/interventional: none disease-specific (orthopedic/hip management as needed).

Experimental / future: gene-axis–directed approaches and improved IGF-1 formulations are areas of interest; no gene therapy is established. (Search ClinicalTrials.gov for active SPIGFD/mecasermin studies.)

Pharmacogenomics / personalized medicine: genotype (GHR vs downstream gene) and GHBP status guide whether IGF-1 replacement (vs other approaches) is rational; IGF1R-defect patients respond poorly to IGF-1 (resistance, not deficiency).

Suggested MAXO terms: MAXO:0000058-type pharmacotherapy / hormone replacement therapy; MAXO:0000088 dietary intervention (hypoglycemia prevention); MAXO:0000079 genetic counseling; MAXO:0000950 supportive care. (Verify exact MAXO IDs with OAK before curation.) CHEBI/therapeutic agent: mecasermin (recombinant IGF-1) — bind via NCIT (e.g., NCIT mecasermin) if no CHEBI term.

Sources: Mecasermin clinical/pharmacoeconomic reviews (NCBI Bookshelf NBK596664/NBK596662); Early rhIGF-1 trial, PMID:8334752; Near-adult height IGFD registry, PMID:40626687; 22-year Saudi cohort (Karger, 2025); NHS England mecasermin policy.

13. Prevention

• Primary prevention: not preventable (monogenic). Genetic counseling for at-risk/consanguineous families and known founder communities is the principal preventive measure; carrier and cascade testing identify at-risk couples.
• Reproductive options: prenatal diagnosis and preimplantation genetic testing (PGT) where the familial variant is known.
• Secondary prevention (early detection): prompt biochemical workup (IGF-1, GH, GHBP) in infants with early growth failure + hypoglycemia enables early diagnosis and timely rhIGF-1 initiation within the critical growth window.
• Tertiary prevention (complication prevention): dosing rhIGF-1 with meals to prevent hypoglycemia; metabolic/bone monitoring; for STAT5B subtype, infection prophylaxis and pulmonary surveillance.
• Immunization / public health / environmental: not applicable (no infectious or environmental etiology).

Sources: MedlinePlus; [GeneReviews/Orphanet genetic-counseling guidance].

14. Other Species / Natural Disease

• Taxonomy: humans (NCBITaxon:9606). The GHR gene and GH–IGF-1 axis are deeply conserved across vertebrates.
• Orthologous genes: Ghr in mouse (NCBI Gene 14600), rat, and other mammals; orthologs in zebrafish, chicken, cattle, etc.
• Naturally occurring / engineered animal disease:
• Mouse: the GHR-knockout ("Laron mouse," Ghr⁻/⁻) is the canonical model — dwarfism, low IGF-1, high GH, obesity, enhanced insulin sensitivity, reduced cancer, and extended lifespan (one of the longest-lived laboratory mouse lines).
• Cattle/poultry: GHR variants underlie growth/dwarf phenotypes (e.g., sex-linked dwarfism in chickens maps to GHR; bovine GHR polymorphisms affect stature/milk).
• Dogs/companion animals: GH-axis growth disorders are recognized in veterinary endocrinology (OMIA catalogues GH/IGF-axis traits across species).
• Comparative biology: the conserved GH→JAK2/STAT5→IGF-1 cascade means model phenotypes (dwarfism + metabolic protection + longevity) closely mirror human Laron syndrome, making it a leading model for aging and cancer-protection research (the GH/IGF-1 longevity axis).
• Transmission / zoonosis: none (genetic, non-communicable).

Suggested terms: NCBITaxon:9606 (human), NCBITaxon:10090 (mouse); OMIA for veterinary GHR phenotypes; VBO for affected breeds (e.g., chicken dwarf lines).

Sources: Guevara-Aguirre 2011, PMID:21325617 (links human to long-lived Ghr−/− mouse); comparative GH/IGF-1 longevity literature (e.g., Bartke/Coschigano Ghr-KO studies).

15. Model Organisms

• Model types: mammalian (mouse, rat), with cellular/in-vitro systems from patient-derived material; zebrafish and cattle/poultry for comparative growth genetics.
• Flagship genetic model — the GHR-knockout / "Laron mouse" (Ghr⁻/⁻):
• Types available: global knockout, plus tissue-specific/conditional (e.g., liver-specific Ghr knockout to dissect hepatic IGF-1's role) and humanized/knock-in lines.
• Phenotype recapitulation (excellent): proportionate dwarfism, very low IGF-1, elevated GH, increased adiposity, enhanced insulin sensitivity, reduced cancer incidence, and markedly extended lifespan — faithfully mirroring the human metabolic/longevity/cancer-protection phenotype.
• Limitations: murine craniofacial/skeletal proportions and the human-specific psychosocial dimension are not captured; the dramatic murine lifespan extension is more pronounced than the (near-normal) human lifespan, so longevity translation must be made cautiously.
• Patient-derived in vitro models: Laron-serum and patient-cell assays demonstrated reduced oxidative DNA damage and increased apoptosis of stressed cells, and genome-wide profiling identified candidate cancer-protection pathways (PMC6627189) — key for the protective-phenotype mechanism.
• Applications: dissecting GH–IGF-1 signaling, aging/longevity biology, cancer chemoprevention, insulin sensitivity/diabetes, and rhIGF-1 pharmacology.
• Resources/databases: MGI / IMPC / KOMP (mouse Ghr alleles), Alliance of Genome Resources, OMIA (cross-species GHR phenotypes), Cellosaurus (patient cell lines).

Sources: Guevara-Aguirre 2011, PMID:21325617; Genome-wide profiling of Laron patients (PMC6627189); Bartke/Coschigano Ghr-KO longevity literature (MGI).

Summary of Key Curation Anchors (for the dismech entry)

• MONDO: MONDO:0008638 · OMIM: #262500 · Orphanet: ORPHA:633 · Category: Mendelian (autosomal recessive).
• Causal gene: GHR (HGNC:4263); broader axis: STAT5B, IGFALS, IGF1, IGF1R, PAPPA2.
• Central mechanism: biallelic GHR LoF → failed JAK2–STAT5B signaling → hepatic IGF-1 deficiency with loss of GH negative feedback (high GH, low IGF-1) → growth-plate chondrocyte failure → severe postnatal short stature; plus a protective metabolic phenotype (low cancer/diabetes).
• Biochemical signature for definitions block: low IGF-1 + normal/high GH + subnormal IGF-1-generation response + low IGFBP-3/ALS ± low GHBP.
• Treatment: rhIGF-1 (mecasermin) replacement (MAXO pharmacotherapy / hormone replacement); GH is ineffective.
• Landmark evidence PMIDs: 21325617 (cancer/diabetes protection, Sci Transl Med), 8334752 (early rhIGF-1 efficacy), 40626687 (near-adult height registry), 21525302 (GHI continuum), plus STAT5B (PMC5974024) and cancer-protection pathways (PMC6627189).

Sources

• OMIM #262500 — Laron Syndrome · OMIM *600946 — GHR · OMIM #245590 — GHISID1 (STAT5B)
• MedlinePlus Genetics: Laron syndrome · NORD: Growth Hormone Insensitivity
• Guevara-Aguirre et al., Sci Transl Med 2011 — PMID:21325617
• Genetic Causes of GHI beyond GHR — PMC7979432 · Genetic defects in the GH–IGF-I axis — PMC3356141
• Continuum of GHI abnormalities — PMID:21525302 · Dominant-negative STAT5B — PMC5974024
• Genome-wide profiling of Laron patients — PMC6627189
• Early rhIGF-1 (Laron) trial — PMID:8334752 · Near-adult height IGFD registry — PMID:40626687 · 22-year Saudi Laron cohort (Karger 2025)
• Mecasermin clinical review — NCBI NBK596664 · NHS England mecasermin policy
• Clinical & molecular features of Laron syndrome — In Vivo 2016 · Brazilian Laron series — PMC7197995
• Zvi Laron / cohort history — Healio · USC: memory advantage study · Scientific American

Curation caveats for dismech: Per the project SOP, every PMID and snippet above must be re-verified with just fetch-reference and just validate-references before entry — treat this report as leads, not ground truth. In particular, confirm exact HPO/GO/CL/UBERON/MAXO/CHEBI IDs with OAK (runoak ... info), and run the NEC preflight against MONDO:0008638 (causal gene = GHR; OMIM 262500) given the GHI/Laron name-and-synonym overlap with the downstream-gene GHI subtypes. Frequency bands (Frequent/Occasional) are qualitative estimates here and need their own quantitative evidence before being committed with a frequency: value.